Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.

Douglas R LangbehnElisabeth M FineAndreas MeierSteven Hersch

Published in: Movement disorders : official journal of the Movement Disorder Society (2022)

The composition of a perimanifest clinical trial population can be defined using preselected PIN thresholds, facilitating the assessment of potential disease-modifying therapies in HD. © 2022 Voyager Therapeutics, Inc. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Keyphrases

clinical trial
phase ii
open label
double blind
study protocol
phase iii
small molecule
systematic review
human health